CHARGEPOINT INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies ChargePoint Investors of a Class Action Lawsuit and Upcoming Deadline
04 déc. 2023 08h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired ChargePoint Holdings.
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
04 déc. 2023 08h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
DOLLAR GENERAL INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Dollar General investors of a Class Action Lawsuit and Upcoming Deadline
01 déc. 2023 22h52 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased the common stock of Dollar General Corp
CHARGEPOINT INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies ChargePoint Investors of a Class Action Lawsuit and Upcoming Deadline
30 nov. 2023 18h42 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired ChargePoint Holdings, Inc.
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
30 nov. 2023 16h30 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
30 nov. 2023 16h30 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
29 nov. 2023 14h50 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX).
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
28 nov. 2023 13h44 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc. (Nasdaq: SLRN) common stock.
SUNPOWER INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies SunPower Investors of a Class Action Lawsuit and Upcoming Deadline
27 nov. 2023 10h01 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired SunPower Corporation.
THE BEAUTY HEALTH COMPANY INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Beauty Health Investors of a Class Action Lawsuit and Upcoming Deadline
22 nov. 2023 15h29 HE
|
Kaplan Fox & Kilsheimer LLP
Beauty Health Investor Notice.